Taysha Gene Therapies, Inc. TSHA Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Taysha Gene Therapies, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Taysha Gene Therapies, Inc.'s operating cash flow?
- Taysha Gene Therapies, Inc. (TSHA) reported operating cash flow of -$40.88M in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s operating cash flow changed year-over-year?
- Taysha Gene Therapies, Inc.'s operating cash flow decreased by 85.6% year-over-year, from -$22.02M to -$40.88M.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s operating cash flow?
- Over 3 years (2021 to 2025), Taysha Gene Therapies, Inc.'s operating cash flow has grown at a -7.3% compound annual growth rate (CAGR), from -$117.04M to -$93.09M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.